Vanderbilt Integrative Cancer Biology Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Mol Imaging Biol. 2011 Oct;13(5):840-52. doi: 10.1007/s11307-010-0399-5.
Metabolism, and especially glucose uptake, is a key quantitative cell trait that is closely linked to cancer initiation and progression. Therefore, developing high-throughput assays for measuring glucose uptake in cancer cells would be enviable for simultaneous comparisons of multiple cell lines and microenvironmental conditions. This study was designed with two specific aims in mind: the first was to develop and validate a high-throughput screening method for quantitative assessment of glucose uptake in "normal" and tumor cells using the fluorescent 2-deoxyglucose analog 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxyglucose (2-NBDG), and the second was to develop an image-based, quantitative, single-cell assay for measuring glucose uptake using the same probe to dissect the full spectrum of metabolic variability within populations of tumor cells in vitro in higher resolution.
The kinetics of population-based glucose uptake was evaluated for MCF10A mammary epithelial and CA1d breast cancer cell lines, using 2-NBDG and a fluorometric microplate reader. Glucose uptake for the same cell lines was also examined at the single-cell level using high-content automated microscopy coupled with semi-automated cell-cytometric image analysis approaches. Statistical treatments were also implemented to analyze intra-population variability.
Our results demonstrate that the high-throughput fluorometric assay using 2-NBDG is a reliable method to assess population-level kinetics of glucose uptake in cell lines in vitro. Similarly, single-cell image-based assays and analyses of 2-NBDG fluorescence proved an effective and accurate means for assessing glucose uptake, which revealed that breast tumor cell lines display intra-population variability that is modulated by growth conditions.
These studies indicate that 2-NBDG can be used to aid in the high-throughput analysis of the influence of chemotherapeutics on glucose uptake in cancer cells.
代谢,尤其是葡萄糖摄取,是与癌症发生和进展密切相关的关键定量细胞特征。因此,开发用于测量癌细胞中葡萄糖摄取的高通量测定法对于同时比较多种细胞系和微环境条件将是非常可取的。本研究有两个具体目标:第一个是开发和验证一种高通量筛选方法,用于使用荧光 2-脱氧葡萄糖类似物 2-[N-(7-硝基苯并-2-恶唑-1,3-二唑-4-基)氨基]-2-脱氧葡萄糖(2-NBDG)定量评估“正常”和肿瘤细胞中的葡萄糖摄取,第二个是开发一种基于图像的、定量的单细胞测定法,使用相同的探针来剖析体外肿瘤细胞群体中代谢变异性的全貌,分辨率更高。
使用 2-NBDG 和荧光微孔板读数器评估 MCF10A 乳腺上皮和 CA1d 乳腺癌细胞系的基于群体的葡萄糖摄取动力学。还使用高内涵自动显微镜和半自动细胞计量图像分析方法在单细胞水平上检查了相同细胞系的葡萄糖摄取。还实施了统计处理来分析群体内变异性。
我们的结果表明,使用 2-NBDG 的高通量荧光测定法是一种可靠的方法,可用于评估体外细胞系中葡萄糖摄取的群体动力学。同样,基于单细胞的图像测定法和 2-NBDG 荧光分析被证明是评估葡萄糖摄取的有效且准确的方法,这表明乳腺癌细胞系显示出受生长条件调节的群体内变异性。
这些研究表明,2-NBDG 可用于辅助高通量分析化学疗法对癌细胞中葡萄糖摄取的影响。